How the contract works
This contract settles at $1 per share if the CDC's measles counter shows 12,500 or more confirmed U.S. cases for 2026, and at $0 if it does not. The price at any moment reflects what traders collectively think the chance of reaching that threshold is โ a contract priced at 0.30, for example, would imply roughly a three-in-ten chance, not this market's actual level. Settlement is based solely on the CDC's published figures between 1 January and 31 December 2026, with the result finalized shortly after the year ends on 1 January 2027. A position in this contract can typically be sold before that date at whatever price the market has moved to in the meantime.
Yes6%
No94%
Probability
How the price has moved
The market consensus sits at 2% across tracked venues, all of that activity concentrated on Polymarket with $357,202 in volume. No multi-day or multi-week price history is available to characterize short-term swings, but a reading this low, on a single-venue market with meaningful volume behind it, indicates traders see the 12,500 threshold as a scenario well outside the range suggested by recent U.S. measles trends, including the 2025 outbreak.
Analysis
Context
Measles was declared eliminated in the United States in 2000, meaning the virus no longer circulated continuously within the country. That status came under threat in 2025 after a large, sustained outbreak centered in West Texas spread into neighboring states, driven largely by clusters of unvaccinated individuals, including in Mennonite communities. The outbreak drew national attention to falling childhood vaccination rates and renewed debate over school vaccine mandates and exemption policies.
This contract asks whether the CDC's official measles case counter will reach 12,500 or more confirmed cases for the full 2026 calendar year. The CDC publishes weekly updates on confirmed measles cases by state, and that counter is the sole reference for settlement. The question does not ask whether an outbreak will occur, since one already has in recent history, but whether its scale in 2026 will dwarf anything previously recorded in the post-elimination era.
The actors who matter here are state and local health departments reporting case data to the CDC, vaccination rates in under-immunized communities, and the CDC itself, which compiles and publishes the national count. No single federal decision determines the outcome; it depends on whether new chains of transmission take hold and how quickly they are contained.
The consensus price of 2% across tracked venues reflects a judgment that a jump to 12,500 cases in a single year would be an extraordinary departure from recent U.S. measles history. The 2025 outbreak, the largest in the post-elimination era, was itself treated as a public health emergency by state officials and drew sustained CDC and media attention, yet it did not approach anywhere near this scale. For 2026 to clear 12,500, the country would need not just a continuation of existing clusters but multiple new, large, geographically dispersed outbreaks sustained over many months โ a pattern that has not occurred domestically since before elimination in 2000.
All of the $357,202 in tracked volume sits on a single venue, Polymarket, which limits the ability to compare pricing across platforms. A single-venue market can still move meaningfully on new information, but the absence of a cross-venue spread here means there is no disagreement between pools of traders to analyze โ only one collective judgment, currently fixed near the low end of the probability scale.
The structural case for a low price is straightforward: measles is extremely contagious, but modern public health response โ rapid identification, ring vaccination, isolation of cases โ has historically kept even significant outbreaks in the hundreds or low thousands rather than tens of thousands. Reaching 12,500 would require either a severe breakdown in that response infrastructure or a substantial, sustained decline in vaccination coverage across many communities simultaneously. Neither is impossible, but both would represent a significant and visible shift from the current trajectory, which is why the market has settled where it has.
What moves the probability
2025 outbreak as baseline
The West Texas-centered outbreak in 2025 is the most recent reference point for how large a U.S. measles event can get under current conditions. It drew intense public health intervention but did not approach the 12,500 threshold, anchoring expectations for 2026 at a much lower level.
Vaccination coverage trends
Declining MMR vaccination rates in specific communities and states raise the risk of new clusters forming. A broad, multi-state decline in coverage would push the probability up meaningfully; coverage holding steady or improving pushes it down.
Speed of public health containment
Rapid state and local response โ contact tracing, targeted vaccination campaigns, school exclusion policies โ has historically contained U.S. outbreaks before they spread nationally. Any visible breakdown in that containment capacity would be the clearest signal the market is underpricing the risk.
CDC reporting cadence and completeness
Because settlement depends entirely on the CDC's published counter, any reporting delays, revisions, or changes in how states submit data could shift the recorded total independent of the actual disease spread, though this is a secondary factor compared to real transmission trends.
The case for
- A new, large outbreak would need to emerge in at least one additional state beyond the 2025 cluster area and sustain active transmission for most of 2026.
- Vaccination exemption rates would need to rise sharply in several populous areas simultaneously, creating multiple pockets of susceptible population large enough to sustain chains of infection.
- Public health containment measures would need to fail or be significantly delayed in at least one of these outbreaks, allowing case counts to compound over many months rather than being contained within weeks.
- The CDC would need to confirm and publish cases at a pace consistent with reaching 12,500 by the 31 December 2026 cutoff, which requires sustained weekly case additions in the hundreds for much of the year.
The case against
- The 2025 outbreak, the largest in the post-elimination era, finished well short of this threshold despite sustained attention and spread across several states.
- National childhood MMR vaccination coverage, while declining in pockets, remains high enough overall that widespread simultaneous outbreaks across many states are historically rare.
- State and local health departments have a track record of containing measles clusters within weeks to a few months once identified, which caps the size of most individual outbreaks.
- Reaching 12,500 would require sustained case growth far outside anything documented in CDC records since measles elimination in 2000, a historical base rate the market is clearly weighting heavily.
What to watch
The key signal is the CDC's weekly measles case counter through 2026, available at cdc.gov/measles/data-research, which will show whether new outbreak clusters are forming beyond the areas affected in 2025. State-level vaccination exemption data released periodically by health departments will indicate whether susceptible populations are growing. Any CDC or state declaration of a new active outbreak, particularly one spanning multiple states, would be the clearest early sign that the market's current pricing is being tested.
Trade this contract
Open on Polymarket
- gas covered
- no trading fee